Walid Shaib is an Oncology physician. OpenAlex indexes 195 publications with 5,670 citations (h-index 36); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1450 Chapel St
Hospital Of Saint Raphael
New Haven, CT 065114405
Telephone
203-789-3034Registry record last updated 29 Oct 2019.
Clinical trials
- Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma
Sponsor: Walid Shaib, MD
- Phase II Randomized Trial of mFOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer
Sponsor: Walid Shaib, MD
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
61 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Exelixis Inc.Program year202572 payments$49,643openpaymentsdata.cms.gov ↗
- JAZZ PHARMACEUTICALS INC.Program year202529 payments$33,367openpaymentsdata.cms.gov ↗
- AstraZeneca Pharmaceuticals LPProgram year202519 payments$18,609openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
25.4%Aromatase Inhibitor9.8%Letrozole63%Anastrozole28%Exemestane9%Part D<11 patientsKinase inhibitor7.6%Brukinsa24%Ibrance22%Jakafi20%Calquence17%Imatinib Mesylate16%Part D<11 patients+ 3 more classes in this area
Metabolism & gastrointestinal
23.9%Serotonin-3 Receptor Antagonist10.3%Ondansetron Hcl100%Part D≥77 patientsProton pump inhibitor3.7%Omeprazole56%Pantoprazole Sodium44%Part D<11 patients+ 5 more classes in this area
Nervous system
19.7%Phenothiazine7.7%Prochlorperazine Maleate100%Part D≥73 patientsOpioid Agonist7.2%Oxycodone Hcl53%Tramadol Hcl27%Morphine Sulfate Er20%Part D<11 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Phase II trial of nivolumab and metformin in patients with treatment-refractory microsatellite stable metastatic colorectal cancer
Journal for ImmunoTherapy of Cancer
2023 - Predictive and Prognostic Effects of Primary Tumor Size on Colorectal Cancer Survival
Frontiers in Oncology
2021
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”